相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease
Dominique P. Germain et al.
CLINICAL GENETICS (2022)
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
Albina Nowak et al.
JOURNAL OF MEDICAL GENETICS (2022)
Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study
Borja Quiroga et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Treatment of Fabry Diseasemanagement with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)
Malte Lenders et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L. Neuen et al.
CIRCULATION (2022)
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)
Malte Lenders et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Assessment of plasma lyso-Gb3for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
Daniel G. Bichet et al.
GENETICS IN MEDICINE (2021)
MRI-visible perivascular spaces as an imaging biomarker in Fabry disease
D. Lyndon et al.
JOURNAL OF NEUROLOGY (2021)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress
PauloC Gregorio et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2021)
Cardiac Involvement in Fabry Disease JACC Review Topic of the Week
Maurizio Pieroni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens
Lavinia Bernea et al.
VACCINES (2021)
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review
Fabio Caputo et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
The benefits and challenges of family genetic testing in rare genetic diseases - lessons from Fabry disease
Dominique P. Germain et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2021)
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review
Daniel Oder et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures
Mehdi Namdar et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Renal Manifestations of Fabry Disease: A Narrative Review
Cassiano Augusto Braga Silva et al.
CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE (2021)
Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort
Albina Nowak et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2020)
Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease
Joao B. Augusto et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2020)
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)
Malte Lenders et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
Yumi Aoyama et al.
INTERNAL MEDICINE (2020)
Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup
Dominique P. Germain et al.
JOURNAL OF MEDICAL GENETICS (2020)
Determinants of cerebral radiological progression in Fabry disease
Simon Korver et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
An expert consensus document on the management of cardiovascular manifestations of Fabry disease
Ales Linhart et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Diagnosis and Screening of Patients with Fabry Disease
Irfan Vardarli et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
Juan Politei
MOLECULAR GENETICS AND METABOLISM (2020)
Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury?
Mohammad Obeidat et al.
ULTRASTRUCTURAL PATHOLOGY (2020)
In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
Malte Lenders et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
Dawn A. Laney et al.
CLINICAL KIDNEY JOURNAL (2020)
Biomarkers in Anderson-Fabry Disease
Irene Simonetta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy
Christoph Wanner et al.
MOLECULAR GENETICS AND METABOLISM (2019)
The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts
Marco Spada et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Proposed Stages of Myocardial Phenotype Development in Fabry Disease
Sabrina Nordin et al.
JACC-CARDIOVASCULAR IMAGING (2019)
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts
Dominique P. Germain et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Fabry disease in cardiology practice: Literature review and expert point of view
Albert Hagege et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2019)
Role of cardiac imaging in Anderson-Fabry cardiomyopathy
Walter Serra et al.
CARDIOVASCULAR ULTRASOUND (2019)
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
Dominique P. Germain et al.
GENETICS IN MEDICINE (2019)
Predictors of Clinical Evolution in Prehypertrophic Fabry Disease
Antonia Camporeale et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2019)
Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients
Dominique P. Germain et al.
CLINICAL GENETICS (2019)
Fabry's disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis
Sen Sheng et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2019)
Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy
Malte Lenders et al.
JOURNAL OF MEDICAL GENETICS (2019)
Quantitative Myocardial Perfusion in Fabry Disease
Kristopher D. Knott et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2019)
Why systematic literature reviews in Fabry disease should include all published evidence
Perry M. Elliott et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2019)
Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
John-Jairo Aguilera-Correa et al.
SCIENTIFIC REPORTS (2019)
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Onas Muentze et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease
Ravi Vijapurapu et al.
HEART (2019)
Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study
Frank Weidemann et al.
MOLECULAR GENETICS AND METABOLISM (2019)
New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases
Renzo Mignani et al.
CLINICAL KIDNEY JOURNAL (2019)
Early Biomarkers of Fabry Nephropathy: A Review of the Literature
Eleonora Riccio et al.
NEPHRON (2019)
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages
Johannes Kraemer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Cardiac Phenotype of Prehypertrophic Fabry Disease
Sabrina Nordin et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2018)
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography
Letizia Spinelli et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2018)
Biomarkers for Diagnosing and Staging of Fabry Disease
Johannes Kraemer et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
Maarten Arends et al.
JOURNAL OF MEDICAL GENETICS (2018)
Fabry disease revisited: Management and treatment recommendations for adult patients
Alberto Ortiz et al.
MOLECULAR GENETICS AND METABOLISM (2018)
European expert consensus statement on therapeutic goals in Fabry disease
Christoph Wanner et al.
MOLECULAR GENETICS AND METABOLISM (2018)
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
Samuel Seidu et al.
PRIMARY CARE DIABETES (2018)
Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
Dan Liu et al.
OPEN HEART (2018)
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
Elfrida R. Benjamin et al.
GENETICS IN MEDICINE (2017)
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn A. Hughes et al.
JOURNAL OF MEDICAL GENETICS (2017)
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
Albina Nowak et al.
MOLECULAR GENETICS AND METABOLISM (2017)
La variante p.Arg118Cys en el gen GLA no causa enfermedad de Fabry. Más evidencias
Cayetana Barbeito-Caamaño et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2017)
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients
Kazuya Tsuboi et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
Maarten Arends et al.
PLOS ONE (2017)
Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease
Rannveig Skrunes et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Basilar Artery Changes in Fabry Disease
R. Manara et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2017)
X-chromosome inactivation in female patients with Fabry disease
L. Echevarria et al.
CLINICAL GENETICS (2016)
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy
Frank Weidemann et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
SGLT2 Inhibitors and the Diabetic Kidney
Paola Fioretto et al.
DIABETES CARE (2016)
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Alberto Ortiz et al.
JOURNAL OF MEDICAL GENETICS (2016)
Determinants of white matter hyperintensity burden in patients with Fabry disease
Natalia S. Rost et al.
NEUROLOGY (2016)
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat
D. P. Germain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Nora Seydelmann et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Electrocardiographic Changes and Arrhythmia in Fabry Disease
Mehdi Namdar
FRONTIERS IN CARDIOVASCULAR MEDICINE (2016)
FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
Renzo Mignani et al.
CLINICAL KIDNEY JOURNAL (2016)
Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease
Vimal Patel et al.
HEART (2015)
Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease
Bouwien E. Smid et al.
JOURNAL OF MEDICAL GENETICS (2015)
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Roberto M. Lang et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)
Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
Johannes Kraemer et al.
PLOS ONE (2015)
Cerebrovascular Involvement in Fabry Disease Current Status of Knowledge
Edwin Kolodny et al.
STROKE (2015)
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch
Frank Weidemann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Outcomes of patients treated through the Canadian Fabry disease initiative
S. M. Sirrs et al.
MOLECULAR GENETICS AND METABOLISM (2014)
Continuous Cardiac Troponin I Release in Fabry Disease
Andreas Feustel et al.
PLOS ONE (2014)
Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Stephen Waldek et al.
BMC NEPHROLOGY (2014)
Role of Serum N-Terminal Pro-Brain Natriuretic,Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease
Caroline J. Coats et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
Raphael Schiffmann et al.
GENETICS IN MEDICINE (2013)
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry
Dominique P. Germain et al.
GENETICS IN MEDICINE (2013)
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
F. Weidemann et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Renal complications of Fabry disease in children
Behzad Najafian et al.
PEDIATRIC NEPHROLOGY (2013)
Value of Electrocardiogram in the Differentiation of Hypertensive Heart Disease, Hypertrophic Cardiomyopathy, Aortic Stenosis, Amyloidosis, and Fabry Disease
Mehdi Namdar et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
Andreas Gal et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2011)
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease
Behzad Najafian et al.
KIDNEY INTERNATIONAL (2011)
Differences in Fabry Cardiomyopathy Between Female and Male Patients Consequences for Diagnostic Assessment
Markus Niemann et al.
JACC-CARDIOVASCULAR IMAGING (2011)
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
Torquil Watt et al.
GENETICS IN MEDICINE (2010)
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Fabry disease
Dominique P. Germain
ORPHANET JOURNAL OF RARE DISEASES (2010)
Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
Chloe Tesmoingt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann et al.
CIRCULATION (2009)
How should proteinuria be detected and measured?
Edmund J. Lamb et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2009)
Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme
David Bodensteiner et al.
GENETICS IN MEDICINE (2008)
Renal manifestations in Fabry disease and therapeutic options
Roser Torra
KIDNEY INTERNATIONAL (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Natural history of the respiratory involvement in Anderson-Fabry disease
S. Magage et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing
Raphael Schiffmann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Maryam Banikazemi et al.
ANNALS OF INTERNAL MEDICINE (2007)
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Christine M. Eng et al.
GENETICS IN MEDICINE (2006)
Relationship between X-inactivation and clinical involvement in Fabry heterozygotes.: Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population
R Dobrovolny et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes
M Fuller et al.
CLINICAL CHEMISTRY (2005)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy
BL Thurberg et al.
KIDNEY INTERNATIONAL (2002)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern?
GL Bakris et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
分享论文
